Industry reports
Editor highlights

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

GBI Research
  • Publication date: July 2011
  • Report price: $ 3 500

Get this report today!

$ 3 500 - 1 User License
$ 7 000 - Site License
$ 10 500 - Corporate License

Summary

Table of Contents

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

Summary

GBI Research, leading business intelligence provider, has released its latest research report, ‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’, which provides insights into major drug failures during 2005–2010. The 20 drugs included in the report belong to key pharmaceutical companies and were undergoing research for a major indication. The report also includes the total expenditure of top pharmaceutical companies in R&D throughout 1996–2009, and an analysis of the financial loss faced by such companies when a drug fails in the late stages of development.

GBI Research discovered that the economic impact of drug failure during late stage development increased in relation to the escalating cost of development for new therapeutic agents. The main cause of drug failure in Phase III, when the efficacy of the drug is already evaluated, is either its safety measures or its ability to demonstrate any additional benefits in a larger population over a longer time period. Pharmaceutical companies have recently invested substantial amounts of money in R&D processes; in order to combat the threat of patent expires of blockbuster drugs, and to increase the chances of discovering a drug which could generate considerable revenue for the company. If a drug receives approval and is patented, companies’ returns are significantly higher than the amount invested in R&D.

The attrition of molecules occurs at various stages of the trial during drug development process. The majority of molecules fail at the initial stages of development, such as pre-clinical studies and Phase I and II. Pharmaceutical companies face huge losses when drugs fail in the late stage of trials, such as Phase III and the post-marketing stage. According to analysis conducted during 2005–2010, it was found that the number of drugs dropped from the pipeline increased from 2003 to 2007 and furthermore decreased from 2007 to 2010. Many drugs have been discontinued during the course of clinical trials, due to safety and efficacy issues. The decision to discontinue the development of a drug is taken by the health authorities and is based on interim analysis. If the drug is not able to demonstrate any additional benefits over existing therapies, or it has issues related to patient safety, the drug fails to receive approval from health authorities.

Scope

The scope of this report includes -
- Identification of top 20 R&D drug failures
- Unmet need in efficacy and safety for all failed drugs
- Phase II results and the reasons for conducting Phase III
- The reasons for failure and lack of available options for a particular therapeutic area
- Conclusion regarding late-stage drug failures based on the analysis of the top 20 drug failures

Reasons to buy

The report will enhance your decision making capability and will allow you to -
- Build an understanding of recent top R&D late stage drug failures
- Analyze the effect of safety and efficacy parameters on major drug failures
- Identify the unmet needs for a particular indication with the highest drug failures
- Understand the most common reasons for drug failure in late stage of development
- Identify the cost involved in R&D by analyzing the expenditure done by top pharmaceutical companies

GBI Research
  • Publication date: July 2011
  • Report price: $ 3 500

Get this report today!

$ 3 500 - 1 User License
$ 7 000 - Site License
$ 10 500 - Corporate License

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Drug Discovery And Development Industry : Latest Reports

Life Sciences BPO Market [Contract Research Organizations (Drug Discovery, Pre-Clinical, Clinical Trials, Medical Writing, Pharmacovigilance, Risk-Based Monitoring, Clinical Data Management, Biostatistics)and Contract Manufacturing Organizations] - Global

Life Sciences BPO Market [Contract Research Organizations (Drug Discovery, Pre-Clinical, Clinical Trials, Medical Writing, Pharmacovigilance, Risk-Based Monitoring, Clinical Data Management, Biostatistics)and Contract Manufacturing Organizations] - Global

  • $ 5 795
  • Industry report
  • February 2014
  • by Transparency Market Research

Life Sciences BPO Market [Contract Research Organizations (Drug Discovery, Pre-Clinical, Clinical Trials, Medical Writing, Pharmacovigilance, Risk-Based Monitoring, Clinical Data Management, Biostatistics)and ...

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

  • $ 5 495
  • Industry report
  • March 2014
  • by Currentpartnering

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and ...

Biopreservation Market (Product Types - Equipment, LIMS, and Media; Applications - Regenerative Medicine, Biobanking, and Drug Discovery) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Biopreservation Market (Product Types - Equipment, LIMS, and Media; Applications - Regenerative Medicine, Biobanking, and Drug Discovery) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • February 2014
  • by Transparency Market Research

This report encompasses market estimations for biopreservation market for the forecast period 2013 to 2019. The market size is forecasted considering 2012 as the base year and is represented in terms of ...


Drug Discovery And Development Industry : Latest Downloads

Global Clinical Trial : Innovation and Technology Trends

  • Industry report
  • April 2014
  • 16 pages

... Complexities, and so on). Within the cro market, the largest segment was that of drug discovery. Based on various analyses, the report also anticipates that the market for clinical data management services ...

Drug Discovery and Development Industry Brief

  • Industry report
  • March 2014
  • 47 pages
  • by Research Paper

... Learn/confirm and predict phase vi registering and labeling (maa) uncertainty confident and drug and disease paediatric strategy & investigation plan scientific advice clinical trial ...

Clinical Trial : Innovation and Technology Trends

  • Industry report
  • December 2013
  • 22 pages

... Company. The transaction positions telerx for further expansion of one of its key vertical businesses 8 nov 12 smo n/a augment number of clinical trial sites to 57. Increase access to patients, conduct ...


Related Market Segments :

Clinical Trial
Drug Development
Clinical Study

Company Reports

Company Profiles

1 Companies

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.